Physician profile
Iyad Baker
NPI 1730341322
$30,732.34
in general payments reported to CMS, 2019-2025
56 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $392 · 2021: $24K · 2022: $946 · 2023: $807 · 2024: $1,709 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Life Technologies Corporation | $23,058.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,019.81 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $983.27 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $725.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $713.21 | 2019-2025 | |
| Pfizer INC. | $372.63 | 2019-2025 | |
| Lilly USA, LLC | $328.37 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $323.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Intra-Sana Laboratories | $281.90 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Horizon Therapeutics Plc | $207.05 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $188.83 | 2020-2025 | Contrave |
| Merck Sharp & Dohme LLC | $168.13 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Amgen INC. | $156.13 | 2021-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $149.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $134.12 | 2019-2024 | Freestyle Libre, Freestyle Libre 3 |
Show all 54 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iyad Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.